<DOC>
	<DOCNO>NCT00192504</DOCNO>
	<brief_summary>MEDI-524 administer single IV dose 3 , 15 , 30 mg/kg child hospitalize RSV infection safe well tolerate .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Immunogenicity Single Intravenous Dose MEDI-524 , Humanized Enhanced Potency Monoclonal Antibody Respiratory Syncytial Virus ( RSV ) , Otherwise Healthy Children Hospitalized With RSV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>All male female child must meet follow criterion : Previously healthy Age £24 month time randomization Gestational age ³36 week gestation Randomization within 24 hour hospitalization Hospitalized low respiratory tract illness ( i.e . RSV bronchiolitis and/or pneumonia ) document positive RSV antigen detection culture respiratory secretion within 72 hour randomization Patients meet follow criterion eligible entry study : Already receive would receive ribavirin antiviral treatment current episode RSV infection prior randomization Required intubation ventilatory support Any medically significant underlie ongoing chronic illness organ system dysfunction know acute illness , RSV infection Known renal impairment , hepatic dysfunction , hematologic abnormality , seizure neurologic disorder immunodeficiency Requirement supplemental oxygen time prior current RSV infection ( brief use oxygen immediate postnatal period treat transient condition allow ) Mechanical ventilation time prior onset current RSV infection Congenital heart disease ( child medically surgically correct patent ductus arteriosus [ PDA ] , small atrial septal defect [ ASD ] ventricular septal defect [ VSD ] allow ) Previous reaction IVIG , blood product , foreign protein Prior use IVIG , RSVIGIV ( RespiGamÒ ) , palivizumab ( SynagisÒ ) , immunoglobulin product within past 2 month Currently receive investigational agent receive investigational agent within last 3 month Prior current participation investigational study therapeutic agent vaccine RSV</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>